FOXP3 Controls Regulatory T Cell Function through Cooperation with NFAT

Yongqing Wu, Madhuri Borde, Vigo Heissmeyer, Markus Feuerer, Ariya D. Lapan, James C. Stroud, Darren L. Bates, Liang Guo, Aidong Han, Steven F. Ziegler, Diane Mathis, Christophe Benoist, Lin Chen, and Anjana Rao

1 The CBR Institute for Biomedical Research and the Department of Pathology, Harvard Medical School, Boston, MA 02115, USA
2 Section on Immunology and Immunogenetics, Joslin Diabetes Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
3 Department of Chemistry and Biochemistry, University of Colorado at Boulder, Boulder, CO 80309, USA
4 Benaroya Research Institute at Virginia Mason and the Department of Immunology, University of Washington, Seattle, WA 98195, USA
5 These authors contributed equally to this work.
6 Present Address: National Research Center for Environment and Health-GSF, Institute of Molecular Immunology, Marchioninistr. 25, D-81377, Munich, Germany.
7 Present Address: UCLA-DOE Institute for Genomics and Proteomics, Los Angeles, CA 90095, USA.
8 Present Address: Molecular and Computational Biology, University of Southern California, 1050 Childs Way, Los Angeles, CA 90089, USA.
*Contact: linchen@usc.edu (L.C.); arao@cbr.med.harvard.edu (A.R.)
DOI 10.1016/j.cell.2006.05.042

SUMMARY

Antigen stimulation of immune cells activates the transcription factor NFAT, a key regulator of T cell activation and anergy. NFAT forms cooperative complexes with the AP-1 family of transcription factors and regulates T cell activation-associated genes. Here we show that regulatory T cell (Treg) function is mediated by an analogous cooperative complex of NFAT with the forkhead transcription factor FOXP3, a lineage specification factor for Tregs. The crystal structure of an NFAT:FOXP2:DNA complex reveals an extensive protein-protein interaction interface between NFAT and FOXP2. Structure-guided mutations of FOXP3, predicted to progressively disrupt its interaction with NFAT, interfere in a graded manner with the ability of FOXP3 to repress expression of the cytokine IL2, upregulate expression of the Treg markers CTLA4 and CD25, and confer suppressor function in a murine model of autoimmune diabetes. Thus by switching transcriptional partners, NFAT converts the acute T cell activation program into the suppressor program of Tregs.

INTRODUCTION

Eukaryotic genes are regulated through the coordinated actions of multiple transcription factors, which typically engage in combinatorial interactions on DNA (Levine and Tjian, 2003; Miner and Yamamoto, 1991). A well-known example of combinatorial transcriptional control is provided by NFAT, four calcium-regulated transcription factors (NFAT1–4) that regulate gene expression in diverse organs including the immune system, muscle, bone, and brain (Crabtree and Olson, 2002; Hogan et al., 2003). NFAT is critical for the differentiation of many cell types including osteoclasts, slow twitch muscle fibers, and effector T cells (Crabtree and Olson, 2002; Hogan et al., 2003). In cardiac, skeletal, and smooth muscle cells, the relevant interactions are between NFAT and GATA proteins (Hogan et al., 2003), whereas in activated T cells, NFAT forms strong cooperative complexes with AP-1 (Fos-Jun) proteins on composite NFAT:AP-1 DNA elements (Rao et al., 1997). Under conditions of productive T cell activation, NFAT:AP-1 complexes turn on expression of activation-associated genes, whereas under conditions of partial activation (i.e., Ca signaling alone), NFAT activates a distinct set of AP-1-independent genes, which encode negative regulators of T cell signaling and contribute to T cell “anergy” (Heissmeyer et al., 2004; Heissmeyer and Rao, 2004; Macian et al., 2002).

The FOXP family of transcription factors (FOXP1–4) plays critical roles in development (Carlsson and Mahlapuu, 2002). A mutation in the DNA binding domain of FOXP2 cosegregates with a congenital speech disorder (Lai et al., 2001), whereas mutations in FOXP3 are linked to autoimmune disease (Ziegler, 2006). Male scurfy mice, which are natural null mutants for the X-linked Foxp3 gene, die 3–4 weeks after birth as a result of aggressive autoimmunity with multiorgan infiltration (Brunkow et al., 2001). Humans with mutations in FOXP3 develop a similar autoimmune syndrome termed IPEX (immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome), characterized by insulin-dependent diabetes, thyroiditis,
massive T cell infiltration into the skin and gastrointestinal tract, high levels of serum autoantibodies, and chronic wasting (Bennett et al., 2001; Wildin et al., 2001). There is compelling evidence that FOXP3 serves as a lineage specification factor for regulatory T cells, a class of T cells that develops primarily in the thymus and is essential for maintaining self-tolerance (Fontenot et al., 2003; Horii et al., 2003; Khattri et al., 2003). T cells from Foxp3-transgenic mice, and primary T cells transduced with Foxp3, acquire many phenotypic and functional characteristics of thymic-derived T regulatory cells (hereafter termed Tregs): increased surface expression of the Treg surface markers CD25, CTLA-4, CD103, and GITR; decreased production of IL-2, IFN-γ, and IL-4 upon restimulation; and ability to suppress effector CD4 T cells in cell culture and in mice (Fontenot et al., 2003; Horii et al., 2003; Khattri et al., 2001, 2003).

Notably, many of the genes regulated by FOXP3 are also target genes for NFAT. The IL2 and IL4 genes are activated by NFAT and repressed by FOXP3, while the CD25 and CTLA4 genes are upregulated by both NFAT and FOXP3 (Hogan et al., 2003; Horii et al., 2003; Rao et al., 1997). The mechanism by which FOXP3 influences the expression of NFAT-dependent genes is unknown. Based on the discovery of an IL2 promoter element that contains a binding site for forkhead proteins adjacent to a binding element for NFAT (Schubert et al., 2001; Wang et al., 2003), it has been suggested that FOXP3 represses IL-2 expression by competing with NFAT for binding to DNA (Schubert et al., 2001; Coffer and Burgering, 2004; Fontenot and Rudensky, 2005). An alternative possibility, based on the finding that NFAT and FOXP3 physically interact in cell lysates (Bettelli et al., 2005), is that FOXP3 represses NFAT-driven cytokine transcription by sequestering NFAT away from DNA. The most intriguing possibility, however, is that both the repressive effect of FOXP3 on cytokine gene expression and its activating effect on the CTLA4 and CD25 Treg marker genes reflect cooperative complex formation between NFAT and FOXP3. We provide evidence for this mechanism here.

RESULTS

FOXP3 Represses NFAT:AP-1-Dependent Transcription and Forms a Cooperative Complex with NFAT

Using reporter assays in Jurkat T cells, we showed that the repressive activity of FOXP3 targets the cooperative NFAT:AP-1 complex rather than other configurations of NFAT (Figures 1 and S1). FOXP3 repressed reporter activity driven by three tandem copies of the murine Il2 promoter ARRE2 element, a prototypical NFAT:AP-1-composite site (Chen et al., 1998; Rao et al., 1997) but did not inhibit the activity of a GAL4 fusion protein containing only the transactivation domain (TAD) of NFAT1 (Luo et al., 1996; Okamura et al., 2000) (Figures S1A and S1B). To exclude the possibility that FOXP3 inhibited Ca2+/calcineurin signaling upstream of NFAT, we coexpressed FOXP3 with a constitutively active (CA) NFAT1 (Macian et al., 2002; Okamura et al., 2000) and treated the cells with cyclosporin A (CsA) to prevent activation of endogenous NFAT. FOXP3 repressed the transcriptional activity of CA-NFAT1 at the ARRE2 NFAT:AP-1 element (Figure 1A) but not at the Tnf promoter k3 element, a palindromic NFκB-like site at which NFAT forms dimers (McCaffrey et al., 1994) (Figure 1B). We conclude that FOXP3 targets nuclear NFAT, acting specifically on NFAT:AP-1 complexes as opposed to dimeric forms of NFAT.

The AP-1 binding sequence in the Il2 promoter ARRE2 site resembles consensus binding sites for forkhead proteins (Carlsson and Mahlapuu, 2002) and for FOXP1 (Wang et al., 2003) (Figure 1C). The forkhead (FKH) domains of three different FOXP proteins, FOXP1, FOXP2, and FOXP3, bound very poorly to the ARRE2 composite site in the absence of NFAT but formed clear cooperative complexes when the NFAT1 DNA binding domain (Rel homology region, RHR) was included in the binding reaction (Figures 1C and S1). This behavior is reminiscent of AP-1, which also binds poorly to this composite site in the absence of NFAT but forms a strong cooperative complex in its presence (Chen et al., 1998; Jain et al., 1993). Thus FOXP3 represses NFAT:AP-1 activity, not by displacing NFAT from NFAT:AP-1 composite sites as suggested previously (Schubert et al., 2001), but rather by forming a cooperative NFAT:FOXP3:DNA complex that resembles the cooperative NFAT:Fos:Jun:DNA complex.

Crystal Structure of a Ternary NFAT:FOXP2:DNA Complex

To analyze the details of the NFAT:FOXP interaction, we crystallized a ternary complex of the NFAT1 RHR and the FOXP2 forkhead domain bound to double-stranded DNA containing the murine Il2 promoter ARRE2 site. The crystal structure was solved by molecular replacement at 2.7 Å (Table S1). Two NFAT1:FOXP2:DNA complexes with a similar overall structure are observed in the asymmetric unit (Figure 2A); in each complex, the RHR of NFAT binds to the 5′ half of the ARRE2 site, while the FOXP2 forkhead domain adopts a typical winged-helix fold and binds to the 3′ half of the ARRE2 site. The two proteins form an extended interaction interface on ARRE2 DNA, burying 614 Å2 of solvent-accessible surface (Figure 2B). The detailed DNA binding interactions are similar to those seen in previously characterized NFAT:DNA and FOXP2:DNA complexes (Chen et al., 1998; Giffin et al., 2003; Jin et al., 2003; Stroud and Chen, 2003; Stroud et al., 2006) (Figures 2C and 2D). Unexpectedly, however, FOXP2 binds different regions of the murine ARRE2 site in the binary FOXP2:DNA and ternary NFAT:FOXP2:DNA complexes (Figure 2E). In the binary complex (Stroud et al., 2006), FOXP2 binds the sequence 5′-GGAATTCTTCA-3′ (site A; FOXP binding sites are underlined, bases in bold match with the in vitro selected sequence), which is a better match with the sequence selected in vitro by Foxp1 (5′-TATTT(G/A)T-3′) (Wang et al., 2003). In the NFAT1:FOXP2:DNA ternary complex, FOXP2 binds the 5′-GGAATTCTTCA-3′ (site A; FOXP binding sites are underlined, bases in bold match with the in vitro selected sequence), which is a better match with the sequence selected in vitro by Foxp1 (5′-TATTT(G/A)T-3′) (Wang et al., 2003).
binds a different, presumably lower-affinity, site 5'-GG AAAATT TT G T T T CA-3' (site B; FOXP binding sites are underlined, bases in bold match with the in vitro selected sequence). Notably, site B which is permissive for NFAT:FOXP interaction is conserved in the human ARRE2 site whereas site A which is nonpermissive is not (Figure 2E), suggesting that the NFAT:FOXP interaction on the Il2 promoter has been maintained in evolution for functional reasons. The extensive protein-protein interactions between NFAT and FOXP (see below) may compensate for potential lower-affinity binding of FOXP2 to the nonconsensus site B, yielding a ternary NFAT:FOXP2:DNA complex that is thermodynamically more stable than the binary FOXP2:DNA complex.

Superposition of the NFAT1:FOXP2:DNA and NFAT1:FOXP3:DNA complexes reveals that NFAT1 binds the 5' half of the ARRE2 element (GGAAA) almost identically in both complexes, whereas FOXP2 occupies the same DNA region as Fos:Jun (Figures 3A and S2A). In both complexes, the ARRE2 DNA appears to undergo adaptive structural changes to maximize protein-protein interactions, bending upward by about 20 degrees in the Fos:Jun:DNA complex to allow the top part of the Fos-Jun coiled-coil to interact with NFAT (Chen et al., 1998).
but bending to the side by about 20 degrees in the NFAT1:FOXP2:DNA complex, apparently to align the NFAT and FOXP interfaces for optimal interaction (Figure S2B). This sideways bend is seen in both complexes of the asymmetric unit, suggesting that the bends are not due to crystal packing but are induced by interactions with the distinct partner proteins.

Although the two copies of NFAT1 in the asymmetric unit show different orientations in the C-terminal domain (RHR-C), the NFAT:FOXP interface is nearly identical in the two NFAT1:FOXP2:DNA complexes (Figure S2C). Helix H2 of FOXP2 packs against the E'F loop of NFAT1, whereas Wing1 of FOXP2 inserts into a large groove formed by the CX loop, the C-terminal stem of the E'F loop, and the fg loop of NFAT1 (Figure 3B). Arg537 of NFAT inserts deeply into the minor groove of DNA, separating the NFAT and FOXP binding sites; this positive charge and the AT-rich sequence in this region may explain the significantly compressed minor groove (Williams and Maher, 2000), which apparently helps to bring the interaction surfaces of NFAT and FOXP2 together (Figure 3C). Overall, the NFAT1:FOXP2 interface is primarily polar and contains small hydrated pockets between major foci of contact. These structural features are similar to those of the NFAT:AP-1 interface (Chen et al., 1998) and may explain why NFAT1 and FOXP2 (like NFAT and AP-1) do not form stable complexes in the absence of DNA (Figure S1F). The FOXP binding residues on NFAT1 are conserved in NFAT2–4 (Figure S3), suggesting a conserved FOXP binding surface in the NFAT family. This structure-based alignment also shows that NFAT uses overlapping as well as distinct residues to bind Fos;Jun and FOXP2, respectively.

**Structure-Based Mutagenesis of NFAT-Interacting Residues in FOXP3**

We took advantage of the high sequence conservation of the forkhead domains of FOXP proteins (Figure 3D) to engineer various structure-guided mutations into the predicted NFAT:FOXP3 interface. We focused on NFAT-interacting residues oriented away from the DNA binding surface of FOXP3, whose mutation was expected to have a minimal effect on protein folding and stability.

(1) RR mutant (E399R E401R): E399 and E401 of FOXP3
are predicted to form salt bridges with the fg loop of NFAT1 (K664R665K666R667) (Figures 3C and 3D). This loop contains conserved positively charged residues in all NFAT proteins (Figure S3). We engineered charge substitutions at these positions into FOXP3, thereby generating the RR mutant. (2) Wing1 insert mutant: Wing1 is uniquely short in the FOXP family compared to other forkhead proteins, and this feature appears critical for binding NFAT (Figure 3B). To interfere sterically with the interaction, we expanded the dimensions of the Wing1 domain of FOXP3. We inserted the additional sequence PDKPG from Wing1 of HNF3 (FOXA3) between E401 and K402 of FOXP3 to generate the Insert mutant. (3) EARR mutant (N361E H365A E399R E401R): To disrupt the NFAT:FOXP3 interaction further, we made an N361E substitution designed to introduce a charge repulsion with E527 of NFAT1, as well as H365A substitution expected to remove favorable interactions between the imidazole ring of H365 and the E’F loop of NFAT. These two mutations were combined with the Wing1 RR mutation to generate the EARR mutant. (4) WRR (N361W E399R E401R) and WWRR (T359W N361W E399R E401R) mutants: A prominent feature of the NFAT1:FOXP3 interaction is the nearly perfect shape complementarity. In an attempt to find a combination of mutations that would completely abrogate the NFAT: FOXP3 interaction, we introduced tryptophan residues in place of N361 and T359 of FOXP3, in the hope that the bulky sidechains would interfere with the interaction by clashing sterically with E527 and I535 of NFAT1, respectively (Figures 3C and 3D). The mutations were introduced in the context of both the RR and Insert mutants with comparable results; only the data for the WRR and WWRR mutants are shown here.

To confirm that the interface mutations did not affect the DNA binding ability of FOXP3, we performed EMSA assays with bacterially expressed wild-type and mutant forkhead domains. The RR, Insert, EARR, and WRR
mutants were comparable to wild-type FOXP3 in their ability to bind a consensus forkhead DNA element (V1P) (Li and Tucker, 1993), although, as expected, they were impaired in their ability to form a cooperative NFAT:FOXP3:DNA complex (Figure S4). Because the forkhead domain of the WWRR mutant formed inclusion bodies when expressed in E. coli, precluding its biochemical characterization, we evaluated the transcriptional competence of this mutant by microarray analysis. A subset of genes was similarly affected (upregulated or downregulated) in retrovirally transduced CD4 T cells expressing either the wild-type or the WWRR mutant FOXP3, whereas others were differentially affected (expression altered by wild-type but not by WWRR mutant FOXP3; V.H. and M.F., unpublished data). Thus while the WWRR mutant is impaired in terms of driving expression of certain genes, presumably those dependent on cooperation with NFAT, it is nonetheless active in driving transcription of other genes, presumably those independent of NFAT:FOXP3 cooperation.

**Mutation of NFAT-Interacting Residues Interferes with Modulation of Gene Expression by FOXP3**

We compared the activities of wild-type and mutant FOXP3 proteins by retrovirally expressing them in primary mouse CD4 T cells. All the interface mutations tested decreased the ability of FOXP3 to inhibit IL-2 expression, as judged by intracellular staining for IL-2 expression after restimulation (Figures 4 and S5). The data are represented both as cytofluorimetric contour plots and as plots of mean fluorescence intensity (MFI) of IL-2 against GFP. In multiple dose-response experiments, the Insert, RR, and EARR mutant proteins showed a 2- to 4-fold shift in their inhibitory capacity, while the tryptophan mutants were even more impaired: the WRR mutation markedly reduced and the WWRR mutation eliminated the ability of FOXP3 to inhibit IL-2 (Figures 4A, 4C, and S5). The impairment was not due to differences in expression levels or subcellular localization: the wild-type and mutant FOXP3 proteins showed equivalent expression and nuclear localization in both NIH 3T3 cells and T cells after retroviral transduction (Figures 4B, 4C, and S6). Thus the ability of FOXP3 to inhibit IL-2 production depends crucially on the integrity of the FOXP3-NFAT interface, suggesting that FOXP3 inhibits IL-2 production by forming a cooperative NFAT:FOXP3:DNA complex which replaces the NFAT:AP-1:DNA complex at composite NFAT:AP-1 sites. Indeed, two sites in the il2 promoter were particularly good matches for a consensus NFAT:FOXP site predicted based on the
crystal structure (Table S2). We cannot rule out, however, that the mutations block interaction with a partner protein other than NFAT.

Retroviral transduction of FOXP3 also leads to increased expression of the Treg markers CTLA-4, CD25, GITR, and CD103 (Hori et al., 2003). In particular, Ctla4 has the characteristics of an NFAT-dependent gene: it is induced in a CsA-sensitive manner by treatments that induce intracellular Ca\(^{2+}\) mobilization, and its promoter contains a composite NFAT:AP-1 element that is a good match for the consensus NFAT:FOXP site predicted based on the crystal structure (Table S2) (Finn et al., 1997; Rao et al., 1997). Indeed, mutations in the NFAT:FOXP3 interface interfered with the ability of retrovirally-transduced FOXP3 to upregulate CTLA-4; the greatest deleterious effect was again observed with the WWRR mutant (Figures 5A and 5B). The mutations had similar but less striking effects on CD25, CD103, and GITR expression (Figures 5A, 5B, and S6). These results suggested that the NFAT:FOXP3 complex could function not only as a repressor of the Il2 gene but also as a direct or indirect activator of the Ctla4 gene, and to a lesser extent the Cd25, Cd103, and Gitr genes.

Chromatin immunoprecipitation (ChIP) experiments confirmed that NFAT1 and FOXP3 could each occupy the Il2, Ctla4, and Cd25 promoters, both in T cells retrovirally transduced with FOXP3 and in “natural” CD4\(^{+}\)CD25\(^{+}\) T regulatory cells that had been expanded with IL-2 (Masteller et al., 2005) (Figure 6). T cells were infected with control or FOXP3-containing IRES-GFP retroviruses, maintained in culture for 4 days (at which point about half of each cell population expressed GFP), then restimulated with PMA and ionomycin. Not only was FOXP3 binding detected at the promoter under these conditions (Figure 6A), but surprisingly, NFAT1 binding to the promoters was considerably increased in FOXP3-expressing cells relative to nonexpressing cells, suggesting stabilization through cooperative binding or increased epitope accessibility (Figure 6B). We also tested expanded Treg populations (about 50% positive for Foxp3 because of overgrowth by contaminating Foxp3-negative cells in the cultures) (Figure 6C). Ionomycin stimulation resulted in binding of NFAT1 as well as Foxp3 to the promoters of the Il2, Ctla4, and Cd25 target genes; binding was substantially diminished in CsA-pretreated cells, again consistent
with cooperative interactions between NFAT and Foxp3 (Figure 6C).

Notably, a truncated FOXP3 protein lacking its N-terminal region (∆N FOXP3) was not capable of either downregulating IL-2 or upregulating CTLA-4 and CD25, despite being similar to wild-type FOXP3 in its expression levels and complete localization to the nucleus (Figure 7). Depending on the target gene involved, the N-terminal region presumably recruits coactivator or corepressor proteins that determine transcriptional activity. This effect may involve interaction with a different region of NFAT or may be entirely independent of NFAT.

**Mutation of the NFAT Contact Surface Impairs the Suppressor Function of FOXP3-Expressing Cells**

Like bona fide regulatory T cells, primary T cells transduced with FOXP3 are capable of suppressing the activity of effector T cells in several animal models of autoimmune disease (Fontenot et al., 2003; Hori et al., 2003; Jaeckel et al., 2005). We asked whether this suppressive function was compromised by handicapping the interaction of FOXP3 with NFAT. We tested the FOXP3 interface mutants in a mouse model of autoimmune diabetes (Katz et al., 1995) in which regulatory T cells play a vital role. When Th1 cells derived from BDC2.5/NOD TCR transgenic...
T cells were transferred into neonatal NOD mice, essentially all recipient animals developed diabetes within 7–20 days (Katz et al., 1995); cotransfer of T cells expressing wild-type FOXP3 protected the animals from disease for a period of at least six weeks (Figure 8). Cotransfer of cells expressing the EARR and WRR mutants of FOXP3 prevented the development of autoimmune disease initially, but the protective effect broke down in 4/9 animals in

Figure 7. The N-Terminal Region of FOXP3 Is Essential for FOXP3 Function

(A) Top, Diagram of FOXP3 indicating the zinc finger, the leucine zipper, and the forkhead (FKH) domain. The N-terminal deletion mutant is indicated. Bottom left, equivalent levels of wild-type and N-terminal deletion mutant FOXP3 in lysates of retrovirally infected 3T3 cells as shown by Western blotting. Actin serves as a loading control. Bottom right, nuclear localization of N-terminal deletion mutant in retrovirally infected 3T3 cells by immunocytochemistry using anti-myc antibody.

(B) T cells from C57BL/6 mice were infected with IRES-GFP retroviruses encoding wild-type FOXP3 or the N-terminal deletion mutant of FOXP3. Four days later, T cells were stained for intracellular CTLA-4 and CD25 without stimulation, and for IL-2 expression after stimulation with anti-CD3 and anti-CD28 for 6 hr.

Figure 8. T Regulatory Function Requires the NFAT:FOXP3 Interface

Th1 cells from BDC2.5/NOD mice were retrovirally transduced with control IRES-Thy1.1, wild-type, or mutant FOXP3-expressing viruses. Two days after infection, Thy1.1-positive cells were sorted and transferred into neonatal NOD mice together with untransduced BDC2.5/NOD effector Th1 cells. Recipient mice were monitored for 6 weeks for presentation of diabetes. The results are compiled from two independent experiments with at least four mice per group in each case.
the EARR group and 7/8 animals in the WRR group by day 20. Protection was also inadequate in mice receiving cells expressing the insert mutant along with effector cells: 2/4 mice in this group developed rapid-onset diabetes, one developed diabetes with a substantial delay, and one was protected until termination of the experiment at day 41. Consistent with the strong effects of the WRR mutation in gene expression assays (Figures 4 and 5), the WRR mutant protein did not confer protection from disease: 9/10 mice that received cells expressing the WRR mutant showed rapid disease onset, thus resembling control groups that received effector cells only or effector cells together with control Thy1.1-transduced T cells. Wild-type and mutant FOXP3 proteins were expressed at equivalent levels and localized to the nucleus (Figure S6).

We analyzed pancreata from mice in each group for insulitis on day 6, before the clinical manifestation of diabetes (Figure S7). At this time point, there was no apparent difference in the degree of insulitis observed in mice from the different groups. However, in mice coinfected with effector cells and cells expressing wild-type FOXP3, the early inflammation is converted to the innocuous condition of “respectful” insulitis (Andre et al., 1996), thus protecting against diabetes. This conversion presumably does not occur in mice that develop diabetes after being given cells expressing FOXP3 interface mutants along with effector cells. At day 20 after transfer, we also evaluated the effector:suppressor T cell ratio in pancreatic lymph nodes of surviving mice, by gating on CD4+ T cells and analyzing the proportion of BDC2.5 TCR+ T cells that were Thy1.1+. (i.e., had been transduced with FOXP3). Surviving mice in all groups showed similar ratios of Thy1.1+ cells relative to CD4+ BDC2.5+ effector T cells in the draining lymph nodes (data not shown), showing that the outbreak of disease is associated with loss of function of the FOXP3-expressing cells, and not with their disappearance. Thus the NFAT:FOXP3 complex controls Treg function but not the migration of FOXP3-expressing T cells to pancreatic lymph nodes or their survival in vivo.

**DISCUSSION**

We have investigated the molecular interactions between NFAT and FOXP3. We have shown that inhibition of NFAT reporter activity by FOXP3 is apparent at NFAT:AP-1 composite sites (Figure 1), and we have solved the crystal structure of an NFAT:FOXP2:DNA complex (Figures 2 and 3). By introducing structure-guided mutations into FOXP3, we have shown that graded disruption of the predicted NFAT:FOXP3 interface results in progressive loss of function of FOXP3, both in gene expression assays and in an in vivo model of autoimmune diabetes in mice (Katz et al., 1995) (Figures 4, 5, and 8). By ChIP assays performed in FOXP3-transduced T cells as well as in Foxp3-expressing regulatory T cells expanded with IL-2, we have confirmed concurrent binding of FOXP3 and NFAT1 to the promoters of the Il2, Cdi4, and Cd25 target genes (Figure 6). We propose that a single transcription factor, NFAT, directs two entirely contrary biological programs—T cell activation and T cell tolerance—by recruiting unrelated transcriptional partners—AP-1 versus FOXP3—to the regulatory regions of appropriate target genes (Figure S8).

How do NFAT:FOXP3 complexes influence gene expression? FOXP3 and Fos-Jun occupy the same region on the ARRE2 site of the Il2 promoter and their binding is expected to be mutually exclusive (Figures 3 and S2). Thus the simplest hypothesis is that FOXP3 competes with AP-1 for cooperative binding with NFAT at a subset of composite NFAT:AP-1 sites, among them the ARRE2 site and the −90 site in the Il2 promoter (Table S2). Nevertheless, simple competition for DNA binding sites is not the entire explanation, as illustrated by the ΔN mutant which has lost the ability to repress IL-2 expression, upregulate CTLA-4 and CD25, and protect against diabetes (Figure 7; V.H. and M.F., unpublished data), even though it contains the forkhead DNA binding domain and both predicted dimerization domains (leucine zipper and zinc finger), is expressed at equivalent levels, and is fully localized to the nucleus. The N-terminal region of FOXP3 that is missing in the ΔN mutant may be actively involved in recruiting transcriptional corepressors and coactivators to the Il2 and Cdi4 promoters, respectively, either independently or through a separate interaction with NFAT in the NFAT:FOXP3 complex.

A remaining question is whether NFAT:FOXP3 cooperation is required for thymic Treg differentiation. CD4+CD25+ thymocytes and peripheral T cells from NFAT1−/−NFAT4−/− double-knockout mice display T regulatory activity in coculture assays (Bopp et al., 2005); however, these cells have elevated nuclear levels of the third family member, NFAT2 (NFATc1) (Ranger et al., 1998); thus it is not yet clear whether Tregs can develop and function in the complete absence of NFAT. To resolve this issue, we are currently introducing our NFAT interface mutations into the endogenous Foxp3 locus. On the other hand, antigen and MHC class II are clearly needed for Treg differentiation in the thymus as well as for the appearance of adaptive/induced Tregs in the periphery (Bluestone and Abbas, 2003). By analogy with the differentiation program of helper T cells (Ansel et al., 2003), we propose that Treg differentiation is initiated by antigen stimulation via NFAT, most likely by imposing a positive feedback loop that converts low-level stochastic expression of Foxp3 into sustained upregulation. This process is likely to be associated with chromatin structural changes that alter the transcriptional competence of Foxp3 target genes as well as the Foxp3 gene itself; consistent with this hypothesis, chromatin at the Il2 promoter is less accessible to MNase digestion in regulatory T cells than in naive CD4 T cells (Su et al., 2004). In addition, Treg function requires restimulation through the TCR (Hori et al., 2003), consistent with a requirement for formation of the cooperative NFAT:FOXP3 complex; this behavior is similar to that of differentiated Th1 and Th2 cells, which produce their signature cytokines only under conditions where NFAT is activated.
Indeed, ChIP analysis shows that Foxp3 binding to Il2, Ctra4, and other target genes in Tregs is stabilized when NFAT is activated (Figure 6 and M.B., unpublished data), in the same manner that NFAT activation stabilizes Gata3 and Tbet binding to their respective target genes (Avni et al., 2002; Lee et al., 2004).

Our data indicate that the immune system employs NFAT as a common regulator both in effector T cells where it forms a transcriptional complex with AP-1 and in regulatory T cells where it complexes with FOXP3. This ensures that activation of self-reactive T cells and activation of regulatory T cells are equally dependent on the immunogenicity of self-antigens, and are therefore balanced. The combinatorial interaction of NFAT with Fos-Jun and FOXP involves both overlapping and distinct interaction surfaces, and individual residues in the overlapping region display distinct modes of interaction with the different partners. In particular, NFAT1 residues R466 and I467 in the CX loop, and T533 in the E’F loop, are critical for Fos-Jun binding (Chen et al., 1998; Macian et al., 2000) but play no apparent role in binding to FOXP2 (Figures 3C and S3). Mutation of these three residues yields NFAT1-RIT, an NFAT1 mutant that is unable to interact with AP-1 (Macian et al., 2000). A constitutively active version of this protein, CA-NFAT1-RIT, is a potent inducer of T cell anergy (Macian et al., 2002) and is also highly effective at cooperating with FOXP3 (V.H., unpublished data). Prolonged antigen stimulation, in the absence of costimulation, leads not only to NFAT-induced anergy but also to the appearance of “adaptive” or “induced” Tregs in the periphery (Apostolou and von Boehmer, 2004; Bluestone and Abbas, 2003; Knoechel et al., 2005; Kretschmer et al., 2005). Thus an attractive strategy for inducing immune tolerance would be to develop small molecule inhibitors that block NFAT:AP-1 interaction without interfering with the interaction of NFAT and FOXP3.

**EXPERIMENTAL PROCEDURES**

**Crystalization of the NFAT1:FOXP3:DNA Ternary Complex**

The forkhead domain of human FOXP3 (residues 502–584) and the Rel homology region (RHR) of human NFAT1 (residues 392–678) were prepared as previously described (Chen et al., 1998; Stroud et al., 2006) and mixed at a 1:1 molar ratio with murine ARRE2 DNA (5’-GGAAAAATTTGTTTCA-3’) in 5 mM HEPES, pH 7.63, 2 mM dithiothreitol (DTT), 0.5 mM EDTA, and 150 mM NaCl. Crystals (space group P21) were grown by hanging drop at 18°C, stabilized in harvest/cryoprotectant buffer, and flash frozen with liquid N2 for cryocryostallography. Statistics are presented in Table S1. Coordinates and structures have been deposited in the RCSB protein database under accession code 2AZS.

**Reporter Assays**

Jurkat cells (10 × 10⁶) were transfected by electroporation with HA-tagged NFAT1 and/or myc-tagged human FOXP3 expression plasmids and luciferase reporter plasmids. Twenty-four hours later, cells were stimulated for 6 hr with 1 μM ionomycin + 10 nM PMA in the presence of 2 mM CaCl₂ and luciferase activity was measured. When CA-NFAT1 was used, endogenous NFAT activity was inhibited 24 hr after transfection by pretreating cells with 1 μM cyclosporin A for 30 min before addition of stimuli. Results are plotted as relative luciferase units after normalization to renilla, except in the case of Figure S1C where luciferase values are normalized to the values obtained in transfections with reporter plasmid alone. In Figures 1A and 1B, values are normalized to the activity observed with CA-NFAT1 in the absence of FOXP3. All results are representative of 2–3 independent experiments.

**Electrophoretic Mobility Shift Assays (EMSAs)**

Binding reactions were performed at room temperature using His-tagged wild-type NFAT1-DD (Macian et al., 2000), His-tagged human FOXP3 forkhead domain (residues 335–419 described in Supplemental Experimental Procedures), and NFAT-AP-1 ARRE2 probe (5’-CAAGGAGAAAAATTTGTTTCAATACAGAAGG-3’) (Jain et al., 1993) in 10 μl of 10 mM Hepes, 5 mM DTT, 100 mM NaCl, 0.2 mM EDTA, and 5% glycerol. DNA-protein complexes were resolved on 6% polyacrylamide gels.

**Primary T Cell Cultures and Retroviral Transductions**

CD4⁺ T cells were isolated by positive selection from mouse spleens and lymph nodes, stimulated with anti-CD3 and anti-CD28 for 48 hr (Ansel et al., 2004), and spin-infected with retrovirus containing supernatant from Phoenix packaging cells transfected with retroviral expression plasmids (KMV IRES-GFP or MSCV IRES-Thy1.1, empty or encoding wild-type or mutant myc-tagged FOXP3). CD4⁺CD25⁺ regulatory T cells were isolated from spleen and lymph nodes of C57Bl/6 mice by positive selection with anti-CD4 magnetic beads (Dynal) followed by two rounds of CD25 positive selection (Miltenyi Biotec). T cells were stimulated for 48 hr with anti-CD3, anti-CD28, and 2000 U/ml of IL-2, then cultured with 2000 U/ml IL-2 (Mastellet al., 2005).

**Flow Cytometry and Intracellular Staining**

T cells were stained intracellularly for CTLA-4 and FOXP3 on days 3 or 4 after retroviral infection, and for cell surface CD25 and GITR on days 2 and 5 after infection, respectively. Staining for IL-2 expression was performed on day 3 after infection after restimulation for 6 hr with anti-CD3 and anti-CD28; Brefeldin A (10 μg/ml) was added during the last 2–3 hr of stimulation. Flow cytometry data are presented both as contour plots and as plots of mean fluorescence intensity (MFI) of IL-2, CTLA-4, and CD25, normalized to that of the GFP-negative population within each sample, against the mean fluorescence intensity of GFP. FOXP3 expression was also evaluated by Western blotting and immunocytochemistry using an IgG-purified rabbit antibody to mouse Foxp3 (Cell-tech Chiroscience).

**Chromatin Immunoprecipitation**

Control and FOXP3-transduced T cells were stimulated with PMA (5 nM) and ionomycin (0.5 μM) for 30 min and chromatin immunoprecipitation was performed as previously described (Ansel et al., 2004) using the following antibodies: anti-67.1 (against a peptide near the N terminus of NFAT1), anti-T2B1 (against a peptide at the C terminus of NFAT1 isoform C), anti-FOXP3 (Cell-tech Chiroscience), anti-myc (9E10), or control rabbit preimmune serum. Binding of FOXP3 and NFAT1 to il2, Ctra4, and Cd25 promoters was determined by real-time PCR. Results show the average and standard deviation of triplicates, with the exception of the CD25 promoter in Figures 6A and 6B, which shows the average of duplicates. Expanded CD4⁺CD25⁺ T regulatory cells were stimulated for 30 min with ionomycin (1 μM) with or without a 30 min preincubation with CsA (2 μM). Sequences of primer pairs are given in Supplemental Experimental Procedures.

**Induction of Diabetes in NOD Mouse Model**

CD4⁺ T cells were isolated from BDC2.5/NOD mice, activated under Th1 conditions (Ansel et al., 2004), and infected as described above with MSCV IRES-Thy1.1 retrovirus, empty or encoding wild-type or mutant FOXP3. Two days after infection, Thy1.1⁺ cells were sorted and transferred into neonatal NOD mice at a 1:2 ratio (0.3 × 10⁶:1 × 10⁶) with untransduced BDC2.5/NOD Th1 cells (“effector” cells). Recipient mice were monitored for diabetes (urinary glucose more than 300 mg/dl).
in two consecutive measurements) for 6 weeks. For histological scoring of insulitis, paraffin sections of formalin-fixed pancreata were examined after hematoxylin-eosin staining.

Supplemental Data
Supplemental Data include two tables, eight figures, Experimental Procedures, and References and can be found with this article online at http://www.cell.com/cgi/content/full/126/2/375/DC1/.

ACKNOWLEDGMENTS
We thank A. Abbas, C. Scheidereit, P.W. Tucker, A. E. Goldfeld, and H. Tong for reagents; J. Goodrich, D. Wuttke, and R. Batey for critical reading of the manuscript and discussion; and the Rao laboratory for helpful discussions. This research was supported by grants from the National Institutes of Health, USA (to A.R., L.C., D.M., C.B., and S.F.Z.), from the W.M. Keck Foundation (to L.C.), from the Juvenile Diabetes Research Foundation (to A.R., D.M., C.B., and S.F.Z.), from the Sandler Program for Asthma Research (to A.R.), and from the American Diabetes Association (to S.F.Z.). M.B. is a fellow of the Ryan Foundation. V.H. was supported by a postdoctoral fellowship from the Cancer Research Institute. M.F. is supported by a postdoctoral fellowship from the Deutsche Forschungsgemeinschaft.

Received: November 29, 2005
Revised: April 12, 2006
Accepted: May 22, 2006
Published: July 27, 2006

REFERENCES


